Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
With mounting competition in Her2-directed breast cancer treatment, Zymeworks’ latecomer struggles to show that it’s better.
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Away from the main small-molecule focus of this year’s Esmo meeting, Keytruda flies the flag for immuno-oncology, including in a little-noticed mesothelioma study.
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.